



20 February 2018

ASX ANNOUNCEMENT

Stage II success for new manufacturing technology: Lidocaine

Medical Developments International Limited (ASX: MVP) is delighted to announce that, in partnership with the CSIRO, it has successfully completed a small-scale production run for Lidocaine using MVP's new manufacturing technology.

Lidocaine has worldwide sales of approximately \$3.4 billion. It is a common local anesthetic and antiarrhythmic drug. It is injected as a local anesthetic for minor surgery and used as a dental anesthetic.

The platform technology is the same as that used for the manufacture of Pentrox. Accordingly, MVP expects the benefits of the new technology to include significant cost reductions, improved consistency in terms of quality and yield, better scalability and improved safety, than that currently used to manufacture the drug.

Chief Executive Officer of MVP, Mr John Sharman, said: "Having completed the small-scale production run for Lidocaine, we are now thinking about manufacturing partners to fully exploit the technology."

Mr. Sharman said: "This is an encouraging result for our development program and ahead of our expectations. Together with the CSIRO we are continuing to work on other drug products which we believe would benefit from our technology."

Dr Paul Savage, Director of CSIRO Biomedical Manufacturing, said "CSIRO is very excited to see that this cutting-edge manufacturing technology can be adapted to new drug molecules of great commercial significance. This partnership with MVP is critical to the CSIRO in finding a commercial pathway to market for this innovation."

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About CSIRO

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) is an Australian Government corporate entity which holds more than 1,800 patents, employs more than 5,000 experts and is based in 55 centers worldwide. Its purpose and functions are undertaken for the benefit of Australia. The CSIRO is Australia's catalyst for innovation and aims to carry out scientific research which assists Australian industry and furthers the interests of the Australian community. The CSIRO Biomedical Manufacturing Group work with biomedical companies to deliver new medical treatments and technologies that benefit millions of people in Australia and overseas.